Table 2

Timing of release of individual participant data from COVID-19 vaccine trials

Phase 3 trialProtocol released before results released?Pledge to share IPDEstimated date of availability
(based on data sharing statement in protocol or publication)
Pfizer phase 2/3; 43 998 participants (NCT04368728)YesYesApril 2025, based on statement in trial protocol that data will be made available ‘24 months after study completion’
Moderna phase 3; 30 420 participants
(NCT04470427)
YesUnclearOctober 2022, based on statement in trial publication that data “may be available … once the trial is complete”
Oxford/AstraZeneca phase 3; 10 300 participants
(ISRCTN89951424)
NoYesDecember 2021, based on statement in trial publication that trial data ‘will be made available when the trials are complete’
Janssen (Johnson & Johnson) phase 3; 44 325 participants
(NCT04505722)
YesYesUnclear. April 2021 publication suggested data availability will begin ‘with publication,’ but as of June, still not listed on Yale Open Data Access Project website.
Novavax phase 3; 30 000 participants
(NCT04611802)
YesNo*We could not locate any other written statement regarding patient-level data sharing. It is not discussed in the trial protocol or publication.
Gamaleya Research Institute phase 3; 33 758 participants
(NCT04530396)
NoYes*May 2021, based on statement in trial publication that data will be made available ‘on completion of clinical trials’
Sinopharm phase 3; 45 000 participants
(NCT04510207)
NoYesDecember 2022, based on statement in trial publication that data will be available between December 2022 and December 2027, with reasonable request to the sponsor and principal investigator.
Sinovac phase 3; 13 000 participants (NCT04582344)YesNo*We could not locate any other written statement regarding patient-level data sharing. It is not discussed in the full-length study protocol. Also, a structured summary of study protocol states ‘Not applicable’ under the availability of data and material.
  • Data current as of 27 June 2021.

  • *According to the ‘Plan to Share IPD’ field in the ClinicalTrials.gov entry.

  • IPD, individual participant data.